A Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group, Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Relapsing-remitting Multiple Sclerosis

Trial Profile

A Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group, Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Relapsing-remitting Multiple Sclerosis

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Aug 2017

At a glance

  • Drugs Corticotropin (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms OPTIONS
  • Sponsors Mallinckrodt Inc.
  • Most Recent Events

    • 23 May 2017 According to a Mallinckrodt plc media release, first patient has been enrolled.
    • 26 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top